Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC925827997;27998;27999 chr2:178712058;178712057;178712056chr2:179576785;179576784;179576783
N2AB894127046;27047;27048 chr2:178712058;178712057;178712056chr2:179576785;179576784;179576783
N2A801424265;24266;24267 chr2:178712058;178712057;178712056chr2:179576785;179576784;179576783
N2BNoneNone chr2:Nonechr2:None
Novex-1NoneNone chr2:Nonechr2:None
Novex-2NoneNone chr2:Nonechr2:None
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: N
  • RefSeq wild type transcript codon: AAT
  • RefSeq wild type template codon: TTA
  • Domain: Ig-78
  • Domain position: 54
  • Structural Position: 134
  • Q(SASA): 0.4693
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
N/K rs749135942 0.216 0.379 N 0.271 0.123 0.165133752707 gnomAD-2.1.1 1.2E-05 None None None None N None 0 0 None 0 0 None 0 None 9.28E-05 8.86E-06 0
N/K rs749135942 0.216 0.379 N 0.271 0.123 0.165133752707 gnomAD-4.0.0 2.73685E-06 None None None None N None 0 0 None 0 0 None 5.6184E-05 0 0 0 1.65673E-05
N/T None None 0.549 N 0.283 0.226 0.376216005999 gnomAD-4.0.0 1.36843E-06 None None None None N None 0 0 None 0 0 None 0 0 1.79896E-06 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
N/A 0.4722 ambiguous 0.5419 ambiguous -0.823 Destabilizing 0.25 N 0.416 neutral None None None None N
N/C 0.5044 ambiguous 0.6388 pathogenic -0.018 Destabilizing 0.992 D 0.513 neutral None None None None N
N/D 0.1754 likely_benign 0.2232 benign -0.265 Destabilizing 0.549 D 0.266 neutral N 0.489844698 None None N
N/E 0.5983 likely_pathogenic 0.6375 pathogenic -0.137 Destabilizing 0.447 N 0.245 neutral None None None None N
N/F 0.8171 likely_pathogenic 0.8453 pathogenic -0.57 Destabilizing 0.85 D 0.509 neutral None None None None N
N/G 0.3206 likely_benign 0.3831 ambiguous -1.177 Destabilizing 0.001 N 0.129 neutral None None None None N
N/H 0.1478 likely_benign 0.1896 benign -0.743 Destabilizing 0.009 N 0.17 neutral D 0.534945056 None None N
N/I 0.6861 likely_pathogenic 0.7605 pathogenic 0.088 Stabilizing 0.896 D 0.514 neutral N 0.515877813 None None N
N/K 0.4573 ambiguous 0.5091 ambiguous -0.058 Destabilizing 0.379 N 0.271 neutral N 0.517319301 None None N
N/L 0.5643 likely_pathogenic 0.5912 pathogenic 0.088 Stabilizing 0.617 D 0.478 neutral None None None None N
N/M 0.6181 likely_pathogenic 0.6621 pathogenic 0.312 Stabilizing 0.977 D 0.469 neutral None None None None N
N/P 0.9245 likely_pathogenic 0.9412 pathogenic -0.186 Destabilizing 0.92 D 0.467 neutral None None None None N
N/Q 0.4436 ambiguous 0.4757 ambiguous -0.617 Destabilizing 0.021 N 0.185 neutral None None None None N
N/R 0.4565 ambiguous 0.5142 ambiguous -0.117 Destabilizing 0.447 N 0.367 neutral None None None None N
N/S 0.1106 likely_benign 0.1302 benign -0.823 Destabilizing 0.334 N 0.303 neutral N 0.483284085 None None N
N/T 0.3205 likely_benign 0.3585 ambiguous -0.486 Destabilizing 0.549 D 0.283 neutral N 0.517455373 None None N
N/V 0.6856 likely_pathogenic 0.7546 pathogenic -0.186 Destabilizing 0.92 D 0.483 neutral None None None None N
N/W 0.9062 likely_pathogenic 0.9379 pathogenic -0.344 Destabilizing 0.992 D 0.526 neutral None None None None N
N/Y 0.324 likely_benign 0.3836 ambiguous -0.1 Destabilizing 0.681 D 0.486 neutral D 0.529827238 None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.